Cardiac Failure Review最新文献_第2页

Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction. 保留射血分数心力衰竭的流行病学、临床特征和病因特异性结局。

Cardiac Failure Review Pub Date : 2023-11-17 eCollection Date: 2023-01-01 DOI: 10.15420/cfr.2023.03

Chris J Kapelios, Bahira Shahim, Lars H Lund, Gianluigi Savarese

引用次数: 0

Biomarkers to Improve Decision-making in Acute Heart Failure. 改善急性心力衰竭决策的生物标志物。

Cardiac Failure Review Pub Date : 2023-10-25 eCollection Date: 2023-01-01 DOI: 10.15420/cfr.2023.08

Rafael de la Espriella, Gonzalo Núñez-Marín, Pau Codina, Julio Núñez, Antoni Bayés-Genís

引用次数: 0

Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction. 保留射血分数的心力衰竭中神经激素调节的病理生理学原理和临床证据。

IF 4.2

Cardiac Failure Review Pub Date : 2023-06-05 eCollection Date: 2023-01-01 DOI: 10.15420/cfr.2022.23

Vincenzo Castiglione, Francesco Gentile, Nicolò Ghionzoli, Martina Chiriacò, Giorgia Panichella, Alberto Aimo, Giuseppe Vergaro, Alberto Giannoni, Claudio Passino, Michele Emdin

{"title":"Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction.","authors":"Vincenzo Castiglione, Francesco Gentile, Nicolò Ghionzoli, Martina Chiriacò, Giorgia Panichella, Alberto Aimo, Giuseppe Vergaro, Alberto Giannoni, Claudio Passino, Michele Emdin","doi":"10.15420/cfr.2022.23","DOIUrl":"10.15420/cfr.2022.23","url":null,"abstract":"Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome resulting from the interaction between cardiac diseases, comorbidities and ageing. HFpEF is characterised by the activation of neurohormonal axes, namely of the renin-angiotensin-aldosterone system and the sympathetic nervous system, although to a lesser extent compared with heart failure with reduced ejection fraction. This provides a rationale for neurohormonal modulation as a therapeutic approach for HFpEF. Nonetheless, randomised clinical trials have failed to demonstrate a prognostic benefit from neurohormonal modulation therapies in HFpEF, with the sole exception of patients with left ventricular ejection fraction in the lower range of normality, for whom the American guidelines suggest that such therapies may be considered. In this review, the pathophysiological rationale for neurohormonal modulation in HFpEF is summarised and the clinical evidence on pharmacological and nonpharmacological approaches backing current recommendations discussed.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"9 ","pages":"e09"},"PeriodicalIF":4.2,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/13/cfr-09-e09.PMC10326668.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9814663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging in Heart Failure with Preserved Ejection Fraction: A Multimodality Imaging Point of View. 保留射血分数的心力衰竭的成像：多模态成像视角。

IF 4.2

Cardiac Failure Review Pub Date : 2023-04-04 eCollection Date: 2023-01-01 DOI: 10.15420/cfr.2022.27

Serkan Ünlü, Özge Özden, Ahmet Çelik

引用次数: 0

Implications of Extra-cardiac Disease in Patient Selection for Heart Transplantation: Considerations in Cardiac Amyloidosis. 心脏外疾病对心脏移植患者选择的影响:对心脏淀粉样变性的考虑。

Cardiac Failure Review Pub Date : 2023-02-01 DOI: 10.15420/cfr.2022.24

Lynn Raju Punnoose, Hasan Siddiqi, Julie Rosenthal, Michelle Kittleson, Ronald Witteles, Kevin Alexander

{"title":"Implications of Extra-cardiac Disease in Patient Selection for Heart Transplantation: Considerations in Cardiac Amyloidosis.","authors":"Lynn Raju Punnoose, Hasan Siddiqi, Julie Rosenthal, Michelle Kittleson, Ronald Witteles, Kevin Alexander","doi":"10.15420/cfr.2022.24","DOIUrl":"https://doi.org/10.15420/cfr.2022.24","url":null,"abstract":"Disease-modifying therapies in both light chain and transthyretin amyloidosis have improved patient functional status and survival. Conceivably, as heart failure may progress despite amyloid therapies, more patients may be considered for heart transplantation. In earlier eras, extra-cardiac amyloid deposits significantly reduced post-heart transplant patient survival and functional status compared to the non-amyloid population. In the modern era, transplant centres have reported improved outcomes in amyloidosis as patient selection has grown more stringent. Importantly, systematic candidate evaluation should assess the degree of extra-cardiac involvement, the effectiveness of disease-modifying therapies and downstream effects on patients' nutrition and frailty. This review outlines such an overall approach while also considering that organ-specific selection criteria may vary between individual transplant centres. A methodical approach to patient evaluation will promote better understanding of the prevalence and severity of extra-cardiac disease in amyloidosis patients referred for heart transplantation and of any disparities in decision outcomes in this population.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"9 ","pages":"e01"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c2/ac/cfr-09-e01.PMC9987512.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9551185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacy Challenges in Cardiac Patient Care During the COVID-19 Pandemic: Lessons Learnt For the Future. 2019冠状病毒病大流行期间心脏病患者护理中的药学挑战:为未来吸取的经验教训。

Cardiac Failure Review Pub Date : 2023-02-01 DOI: 10.15420/cfr.2022.20

Andrew McRae

引用次数: 0

Remote Patient Monitoring for Patients with Heart Failure: Sex- and Race-based Disparities and Opportunities. 心力衰竭患者的远程患者监护：基于性别和种族的差异与机遇。

IF 4.2

Cardiac Failure Review Pub Date : 2023-02-01 DOI: 10.15420/cfr.2022.22

Ioannis Mastoris, Ersilia M DeFilippis, Trejeeve Martyn, Alanna A Morris, Harriette Gc Van Spall, Andrew J Sauer

{"title":"Remote Patient Monitoring for Patients with Heart Failure: Sex- and Race-based Disparities and Opportunities.","authors":"Ioannis Mastoris, Ersilia M DeFilippis, Trejeeve Martyn, Alanna A Morris, Harriette Gc Van Spall, Andrew J Sauer","doi":"10.15420/cfr.2022.22","DOIUrl":"10.15420/cfr.2022.22","url":null,"abstract":"Remote patient monitoring (RPM), within the larger context of telehealth expansion, has been established as an effective and safe means of care for patients with heart failure (HF) during the recent pandemic. Of the demographic groups, female patients and black patients are underenrolled relative to disease distribution in clinical trials and are under-referred for RPM, including remote haemodynamic monitoring, cardiac implantable electronic devices (CIEDs), wearables and telehealth interventions. The sex- and race-based disparities are multifactorial: stringent clinical trial inclusion criteria, distrust of the medical establishment, poor access to healthcare, socioeconomic inequities, and lack of diversity in clinical trial leadership. Notwithstanding addressing the above factors, RPM has the unique potential to reduce disparities through a combination of implicit bias mitigation and earlier detection and intervention for HF disease progression in disadvantaged groups. This review describes the uptake of remote haemodynamic monitoring, CIEDs and telehealth in female patients and black patients with HF, and discusses aetiologies that may contribute to inequities and strategies to promote health equity.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"9 ","pages":"e02"},"PeriodicalIF":4.2,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/01/cfr-09-e02.PMC9987513.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9866960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of Imaging in Cardiomyopathies. 影像学在心肌病中的作用。

Cardiac Failure Review Pub Date : 2023-01-01 DOI: 10.15420/cfr.2022.26

Vincenzo Castiglione, Alberto Aimo, Giancarlo Todiere, Andrea Barison, Iacopo Fabiani, Giorgia Panichella, Dario Genovesi, Lucrezia Bonino, Alberto Clemente, Filippo Cademartiri, Alberto Giannoni, Claudio Passino, Michele Emdin, Giuseppe Vergaro

{"title":"Role of Imaging in Cardiomyopathies.","authors":"Vincenzo Castiglione, Alberto Aimo, Giancarlo Todiere, Andrea Barison, Iacopo Fabiani, Giorgia Panichella, Dario Genovesi, Lucrezia Bonino, Alberto Clemente, Filippo Cademartiri, Alberto Giannoni, Claudio Passino, Michele Emdin, Giuseppe Vergaro","doi":"10.15420/cfr.2022.26","DOIUrl":"https://doi.org/10.15420/cfr.2022.26","url":null,"abstract":"Imaging has a central role in the diagnosis, classification, and clinical management of cardiomyopathies. While echocardiography is the first-line technique, given its wide availability and safety, advanced imaging, including cardiovascular magnetic resonance (CMR), nuclear medicine and CT, is increasingly needed to refine the diagnosis or guide therapeutic decision-making. In selected cases, such as in transthyretin-related cardiac amyloidosis or in arrhythmogenic cardiomyopathy, the demonstration of histological features of the disease can be avoided when typical findings are observed at bone-tracer scintigraphy or CMR, respectively. Findings from imaging techniques should always be integrated with data from the clinical, electrocardiographic, biomarker, genetic and functional evaluation to pursue an individualised approach to patients with cardiomyopathy.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"9 ","pages":"e08"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b3/a4/cfr-09-e08.PMC10326670.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9808398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Defining Heart Failure Based on Imaging the Heart and Beyond. 基于心脏成像及其他技术来定义心力衰竭。

Cardiac Failure Review Pub Date : 2023-01-01 DOI: 10.15420/cfr.2022.29

Fraser J Graham, Antonio Iaconelli, Piotr Sonecki, Ross T Campbell, David Hunter, John Gf Cleland, Pierpaolo Pellicori

引用次数: 0

Treatment of Persistent Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation on Adequate Oral Anticoagulation: Pathways of Care for All-comers and Heart Failure Patients. 充分的口服抗凝治疗房颤患者持续性左心耳血栓:对所有患者和心力衰竭患者的护理途径。

Cardiac Failure Review Pub Date : 2023-01-01 DOI: 10.15420/cfr.2022.28

Josip Katic, Josip Andelo Borovac

{"title":"Treatment of Persistent Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation on Adequate Oral Anticoagulation: Pathways of Care for All-comers and Heart Failure Patients.","authors":"Josip Katic, Josip Andelo Borovac","doi":"10.15420/cfr.2022.28","DOIUrl":"https://doi.org/10.15420/cfr.2022.28","url":null,"abstract":"In patients with AF, the presence of left atrial/left atrial appendage (LA/LAA) thrombus is related to an increased risk of thromboembolic events. Anticoagulation therapy, either with vitamin K antagonists or novel oral anticoagulants (NOACs) is therefore mandatory in AF with LA/LAA thrombus in order to lower the risk of stroke or other systemic embolic events. Despite the efficacy of these treatments, some patients will have persistent LAA thrombus remaining or may have contraindications to oral anticoagulation. Currently, little is known about the occurrence, risk factors and resolution rate of LA/LAA thrombus in patients who are already under optimal chronic oral anticoagulation, including vitamin K antagonists or NOACs. The common action in clinical practice in this scenario is switching from one to another anticoagulant drug exhibiting a different mechanism of action. Repeated cardiac imaging is then advised within several weeks to visually verify thrombus dissolution. Finally, there is a substantial scarcity of data on the role and optimal use of NOACs after LAA occlusion. The aim of this review is to critically evaluate data and provide up-to-date information on the best antithrombotic strategies in this challenging clinical scenario.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"9 ","pages":"e05"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b1/a4/cfr-09-e05.PMC10311400.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9746519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0